TREAT

Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT)

Gold Spirometry

GOLD SPIROMETRIC CRITERIA FOR COPD SEVERITY1
I: Mild COPD
• FEV1/FVC < 0.7
• FEV1 ≥ 80% predicted
At this stage, the patient may not be aware that their lung function is abnormal.

II: Moderate COPD
• FEV1/FVC < 0.7
• 50% ≤ FEV1 < 80%
predicted Symptoms usually progress at this stage, with shortness of breath typically developing on exertion.

III: Severe COPD
• FEV1/FVC < 0.7
• 30% ≤ FEV1 < 50% predicted
Shortness of breath typically worsens at this stage and often limits patients’ daily activities. Exacerbations are especially seen beginning at this stage.

IV: Very Severe COPD
• FEV1/FVC < 0.7
• FEV1 < 30% predicted or FEV1 < 50% predicted plus chronic respiratory failure
At this stage, quality of life is very appreciably impaired and exacerbations may be life-threatening.

GOLD

NCBI PubMED

http://www.ncbi.nlm.nih.gov/pubmed/

ABG Quiz

ABG Online Quiz

Take the quiz here

ATP III

Third Report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults

JUPITER TRIAL

JUPITER trial (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin trial)
http://www.brighamandwomens.org/preventivemedicine/Research/Circv108p2292.pdf

Surviving Sepsis


Surviving Sepsis Campaign Statement on Glucose Control in
Severe Sepsis (June 2009*)
There is insufficient information from randomized controlled trials to
determine the optimal target range of blood glucose in the severely septic
patient. (1) The NICE-SUGAR trial is the largest most compelling study to
date on glucose control in ICU patients given its inclusion of multiple ICUs
and hospitals, and a more general patient population. (2) Based on the
results of this trial, we recommend against intravenous insulin therapy
titrated to keep blood glucose in the normal range (80-110 mg/dl) in
patients with severe sepsis. It is clear that attempts to normalize blood
glucose with IV insulin during critical illness results in higher rates of
hypoglycemia. (1,3) Until additional information is available, teams
seeking to implement glucose control should consider initiating insulin
therapy when blood glucose levels exceed 180 mg/dL with a goal blood
glucose approximating 150 mg/dl as was observed in the beneficial arm
of the NICE-SUGAR trial.
1) Griesdale DE, de Souza RJ, van Dam RM, Heyland DK, Cook DJ,
Malhotra A, Dhaliwal R, Henderson WR, Chittock DR, Finfer S,
Talmor D. Intensive insulin therapy and mortality among critically ill
patients: a meta-analysis including NICE-SUGAR study data. CMAJ.
2009 Apr 14;180(8):799-800.
2) NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY, Blair
D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR,
Hébert PC, Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell
I, Myburgh JA, Norton R, Potter J, Robinson BG, Ronco JJ. Intensive
versus conventional glucose control in critically ill patients. N Engl J
Med. 2009 Mar 26;360(13):1283-97. Epub 2009 Mar 24
3) Wiener RS, Wiener DC, Larson RJ. Benefits and risks of tight glucose
control in critically ill adults: A meta-analysis. JAMA 2008;300:933–
44
*This revised recommendation has been issued by Surviving Sepsis Campaign (SSC)
Guidelines Committee Subgroup for Glucose Control; R. Phillip Dellinger, MD, FCCM, the 2008
SSC Guidelines Chair; and the SSC Executive Committee. Posted on the SSC Web site and list
serve 6/12/2009.

Rifle Criteria

Rifle


by sister's request

Comunity Acquired Pneumonia

http://www.thoracic.org/sections/publications/statements/pages/mtpi/idsaats-cap.html

Joint Statement PSMID PCCP

Cap Guidelines 2004

The GOLD global strategy for the diagnosis, management, and prevention of COPD is presented in its guideline documents, which are freely available on the GOLD Website

ANKI

http://ichi2.net/anki


Flashcard application


-- Post From My iPhone